Outcome of the Board Meeting and disclosure under Regulation 30 of SEBI(Listing Obligations & Disclosure Requirements) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs' board met on June 18, 2025 and approved several strategic moves. It authorised Managing Director N. Aravind to complete the acquisition of AMR Pharma India Private Limited and to explore acquiring Bonn Schtering Bio Sciences in Pondicherry. The board also announced that its Chennai facility has received FDA permission to manufacture and sell medicines. Further, the company plans to set up a subsidiary focused on AI and Machine Learning applications for pharma, drug monitoring, clinical research, medical imaging, diagnostics, e-pharmacy and medical tourism. Lastly, the MD was authorised to sign agreements with state- and district-wise channel partners across India to sell the company's own medicine brands.
This is a growth-oriented board update with multiple positive triggers — fresh FDA clearance adds revenue visibility, the proposed acquisitions and new subsidiary signal expansion into adjacent high-growth areas, and the channel partner push supports domestic distribution. Short-term sentiment should be supportive, though execution risk on the acquisitions and new venture remains.